Washington University School of Medicine
St Louis, Missouri, 63110, United States
NCT Number: NCT05923242
Childhood cancer survivors are at an increased risk of cardiac toxicity due to prior anti-cancer therapy. However, adherence to cardiac screening in this population remains low. This study aims to assess the feasibility of an mHealth motivational interviewing platform called Computerized Authoring Intervention Software (CIAS) in childhood cancer survivors. Participants will be recruited from the Childhood Cancer Survivorship Study.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
St Louis, Missouri, 63110, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
CIAS is a web based intervention. The CIAS tool walks the participant through a Motivational Interviewing process whereby they think through the reasons for and against completing screening. CIAS makes use of an automated avatar (Emmi) who is programed to ask them questions and lead them through several topic areas related to screening. The CIAS pathways include options for participants to request a link of resources after they complete each session and for patients to request a list of the cancer treatments listed in their study records in order to confirm their understanding of their cancer history.
Time frame: From baseline survey to post-test survey (expected to be about 1 week)
Patients will be asked about their knowledge of echocardiograms and the effects of their treatment on health on a 3 point scale consisting of possible answers of yes, no, and "don't know", with "don't know" being scored as incorrect. The scoring will be the summary of correct responses.
Time frame: From baseline survey to post-test survey (expected to be about 1 week)
Patients will be asked about their confidence in getting an echocardiogram on a Likert scale with multiple choice between 0 to 10 with 0 indicating not at all sure and 10 indicating extremely sure. Scores will range from 0 and 10 with a higher value indicating higher confidence.
Time frame: From baseline survey to post-test survey (expected to be about 1 week)
Patients will be asked about their perceived choice of getting an echocardiogram on a 5-point Likert scale with 1 indicating disagree strongly and 5 indicating agree strongly. Scores will range from 3 to 15 with a higher score indicating higher perceived choice.
Time frame: From baseline survey to post-test survey (expected to be about 1 week)
Patients will be asked about the effects of social norms/influence on a 5-point Likert scale with 1 indicating disagree strongly and 5 indicating agree strongly. Scores will range from 6 to 30 with a higher score indicating more effect of social norms and influence on the patient's decision.
Time frame: From post-test survey to 1 month follow-up (expected to be about 1 month and 1 week)
Movement toward screening will consist of checking if patient made a plan to set an appointment with healthcare provider to discuss screening, made an appointment to discuss screening, had appointment to discuss screening, scheduled screening, or obtained screening, and if this plan changed between post-test survey and 1 month follow-up.
Time frame: From baseline survey to post-test survey (expected to be about 1 week)
Patients will be asked about their perceived risk of having heart problems on a 5 point scale, with 1 indicating no likelihood of heart problems, and 5 indicating extremely likely. Scores will range from 1 to 5 with a higher score indicating more perceived risk.
Time frame: From baseline survey to post-test survey (expected to be about 1 week)
Patients will be asked about their perceived severity of heart problems on a 5 point scale, with 1 indicating not serious and 5 indicating extremely serious. Scores will range from 1 to 5 with a higher score indicating higher perceived severity.
Time frame: From baseline survey to post-test survey (expected to be about 1 week)
Patients will be asked about their perceived barriers to getting an echocardiogram on a 5-point Likert scale with 1 indicating disagree strongly and 5 indicating agree strongly. Scores will range from 6 to 30 with a higher score indicating fewer perceived barriers.
Time frame: From baseline survey to post-test survey (expected to be about 1 week)
Patients will be asked about their perceived benefits of getting an echocardiogram on a 5-point Likert scale with 1 indicating disagree strongly and 5 indicating agree strongly. Scores will range from 6 to 30 with a higher score indicating more perceived benefits.
Time frame: From baseline survey to post-test survey (expected to be about 1 week)
Patients will be asked about their overall self-efficacy of getting an echocardiogram on a 5-point Likert scale with 1 indicating disagree strongly and 5 indicating agree strongly. Scores will range from 3 to 15 with a higher score indicating higher overall self-efficacy.
Time frame: From baseline survey to post-test survey (expected to be about 1 week)
Patients will be asked about their worry about having heart problems on a 5-point scale with 1 indicating not worried at all and 5 indicating extremely worried. Scores will range from 1 to 5 with a higher score indicating more worry.
Time frame: From baseline survey to post-test survey (expected to be about 1 week)
Patients will be asked about their intentions of getting an echocardiogram on a 5-point Likert scale with 1 indicating disagree strongly and 5 indicating agree strongly. Scores will range from 3 to 15 with a higher score indicating a higher intention of getting an echocardiogram.
Time frame: From baseline survey to post-test survey (expected to be about 1 week)
Patients will be asked about their perceived importance of getting an echocardiogram on both a Likert scale with multiple choice between 0 to 10 with 0 indicating not at all important and 10 indicating extremely important, and a 5-point Likert scale with 1 indicating disagree strongly and 5 indicating agree strongly. Scores will range from 8 to 50 with a higher value indicating higher perceived importance.
Time frame: From baseline survey to post-test survey (expected to be about 1 week)
Patients will be asked about their decision-making readiness in getting an echocardiogram on a Likert scale with multiple choice between 0 to 10 with 0 indicating not at all ready and 10 indicating extremely ready. Scores will range from 0 to 10 with a higher score indicating higher decision-making readiness.
Time frame: Through the second CIAS session (expected to be about 1 week)
This will be defined as the total time spent on the app during session 1 and session 2.
Time frame: Through the second CIAS session (expected to be about 1 week)
This will be defined as the total number of modules started and total number of modules completed on the app during session 1 and session 2.
Time frame: Through the second CIAS session (expected to be about 1 week)
This will be defined as the total number of sessions started and total number of sessions completed on the app during session 1 and session 2.
Washington University School of Medicine
Other
Evaluation of Cardiovascular Health Outcomes Among Survivors 2 (ECHOS2) Pilot Intervention: Translating ECHOS Into an mHealth Platform
Acronym: ECHOS2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04409379
Acute Leukemia, Cardiac Toxicity
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT04889755
Childhood Cancer, Mental Disorders
Boston, Massachusetts, United States
View Trial DetailsNCT03790943
Cardiac Dysfunction, Cardiotoxicity
Basel, Canton of Basel-City, Switzerland
View Trial DetailsNCT03938324
Anemia, Anemia, Hemolytic
Durham, North Carolina, United States
View Trial Details